摘要
目的:探讨乳腺癌患者行新辅助化疗对癌组织ER、PR、HER-2、Ki-67表达的影响。方法:择取2015年6月-2019年6月本院66例乳腺癌外科手术病例,全部患者术前均接受新辅助化疗。化疗前穿刺活检,术后病理组织学检查,测定患者癌组织ER、PR、HER-2、Ki-67蛋白,比较观察阳性表达情况。结果:ER、PR、HER-2新辅助化疗前后阳性率比较(47.62%vs 49.21%、63.49%vs 65.08%、79.37%vs 77.78%),差异均无统计学意义(χ^2=1.754、1.622、2.315,P>0.05)。Ki-67新辅助化疗后阳性率(65.08%)明显低于化疗前(77.78%),差异有统计学意义(χ^2=3.452,P<0.05)。结论:乳腺癌患者行新辅助化疗基本不会改变癌组织ER、PR、HER-2表达,但会造成Ki-67表达水平降低,可用于预测乳腺癌新辅助化疗效果。
Objective:To explore the effect of neoadjuvant chemotherapy on the expression of ER,PR,HER-2,Ki-67 in breast cancer.Method:From June 2015 to June 2019,66 cases of breast cancer surgery in our hospital were selected.All patients received neoadjuvant chemotherapy before operation.The expression of ER,PR,HER-2,Ki-67 protein in cancer tissue were measured and compared.Result:There were no statistically significant differences in the positive rates of ER,PR and HER-2 before and after neoadjuvant chemotherapy(47.62%vs 49.21%,63.49%vs 65.08%,79.37%vs 77.78%;χ^2=1.754,1.622,2.315;P>0.05).The positive rate of Ki-67 after neoadjuvant chemotherapy(65.08%)was significantly lower than that before chemotherapy(77.78%),the difference was statistically significant(χ^2=3.452,P<0.05).Conclusion:The expression of ER,PR and HER-2 in breast cancer tissues will not be changed by neoadjuvant chemotherapy,but the expression level of Ki-67 will be decreased,which can be used to predict the effect of neoadjuvant chemotherapy.
作者
黄湘秦
HUANG Xiangqin(Fujian Provincial Jinshan Hospital,Fuzhou 350001,China)
出处
《中外医学研究》
2020年第26期52-54,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
乳腺癌
新辅助化疗
雌激素受体
孕激素受体
阳性表达
Breast cancer
Neoadjuvant chemotherapy
Estrogen receptor
Progesterone receptor
Positive expression
